Subdermal Contraceptive Implants Market
Report ID: SQMIG35A4130
Report ID: SQMIG35A4130
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A4130 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
170
|Figures:
79
Global Subdermal Contraceptive Implants Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.29 Billion in 2025 to USD 2.32 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).
The global subdermal contraceptive implants industry includes devices placed under the skin that release progestin to prevent pregnancy for up to three years. It matters because it provides women a low maintenance, effective alternative to oral pills, cutting unintended pregnancies and health costs.
In the decade adoption surged in emerging economies as governments added implants to family planning programs, illustrated by Kenya’s 2020 rollout that doubled implant use within two years. This expanding user base drives market growth. Another pivotal factor driving the subdermal contraceptive implants market is the growing emphasis on long acting reversible contraception in health strategies, which raises demand for cost effective solutions. When governments fund national family planning, they favor methods that cut repeat clinic visits, and implants satisfy that need by providing three years of protection from a single insertion. Scale lowers unit prices, prompting insurers to add implants to coverage, illustrated by France’s 2022 reimbursement policy that lifted prescription volume. Manufacturers respond by developing next generation devices with smaller inserters and biodegradable rods, expanding significant opportunities in adolescent programs and remote clinics.
How is AI improving patient adherence in the subdermal contraceptive implants market?
AI improves patient adherence in the subdermal contraceptive implants market by integrating predictive analytics, personalized reminders, and real‑time health monitoring. AI algorithms analyze patient demographics, lifestyle patterns and prior contraceptive use to forecast when users may miss follow‑up visits or experience side‑effects. The insights trigger mobile notifications that remind patients of upcoming appointments, provide medication‑related education, and suggest coping strategies for discomfort. Telehealth platforms embed these tools, allowing clinicians to remotely adjust implant parameters or schedule removals. By automating engagement, AI reduces drop‑out rates, builds trust, and supports clinicians in delivering consistent care. The technology also aggregates anonymized data, helping manufacturers refine implant designs and counseling materials, ultimately strengthening market confidence.
In March 2024 Merck introduced an AI‑driven adherence app for its Nexplanon implant, demonstrating how intelligent reminders and symptom tracking can boost user compliance and drive market growth.
Market snapshot - (2026-2033)
Global Market Size
USD 1.2 Billion
Largest Segment
Single-Rod Contraceptive Implants
Fastest Growth
Single-Rod Contraceptive Implants
Growth Rate
7.6% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global subdermal contraceptive implants market is segmented by product type, hormone type, duration of action, application, end user, distribution channel and region. Based on product type, the market is segmented into Single-Rod Contraceptive Implants and Two-Rod Contraceptive Implants. Based on hormone type, the market is segmented into Etonogestrel Implants, Levonorgestrel Implants and Others. Based on duration of action, the market is segmented into Up to 3 Years, 3–5 Years and Above 5 Years. Based on application, the market is segmented into Long-Acting Reversible Contraception (LARC), Family Planning and Birth Control. Based on end user, the market is segmented into Hospitals, Gynecology Clinics and Ambulatory Surgical Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Government & Public Health Programs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Etonogestrel implants segment dominates with large subdermal contraceptive implants market share because it offers a well‑established safety profile that clinicians trust, coupled with a convenient one‑year insertion schedule that aligns with routine reproductive health visits. The long‑standing clinical data reduce provider hesitation, while the single‑rod design simplifies insertion and removal, lowering training requirements. These factors drive consistent preference among prescribers and reinforce its leadership in the Subdermal Contraceptive Implants Market and underpin its market share growth.
As per subdermal contraceptive implants market outlook, levonorgestrel implants segment is experiencing the strongest growth momentum because recent advancements have extended its duration of action, appealing to users seeking longer protection without repeat procedures. Enhanced efficacy and increasing awareness among providers are driving adoption, positioning this segment as a key catalyst for market expansion.
As per subdermal contraceptive implants market forecast, long‑acting reversible contraception application segment dominates because it directly aligns with global health priorities to reduce unintended pregnancies, prompting ministries and health systems to prioritize these devices. Its proven efficacy and minimal user compliance requirements make it a preferred option for large‑scale programs, encouraging bulk procurement and supportive reimbursement policies, which together cement its leading position in the Subdermal Contraceptive Implants Market and drive sustained investment across healthcare networks.
Meanwhile, family planning application segment is witnessing rapid expansion because community outreach initiatives increasingly incorporate contraceptive implants as a cornerstone of reproductive health education. Growing acceptance among women of reproductive age, coupled with targeted funding for preventive services, fuels demand, positioning this application as a burgeoning growth engine for the overall market.
To get detailed segments analysis, Request a Free Sample Report
The region benefits from a mature healthcare infrastructure that supports advanced reproductive health services and a high level of clinical adoption among providers. Strong regulatory pathways and well‑established reimbursement mechanisms create a stable environment for manufacturers and suppliers. Robust research and development capabilities, combined with significant investment in medical innovation, drive continuous product improvements and new entrant entry. Consumer awareness of long‑acting reversible contraception is high, reflecting effective public health campaigns and comprehensive patient education. Partnerships between pharmaceutical firms and health systems further accelerate market penetration, while a culture of preventive health sustains demand across diverse demographic groups. These synergistic factors collectively cement North America’s leading position.
As per subdermal contraceptive implants market regional outlook, United States is characterized by widespread clinical acceptance and a well‑integrated supply chain. The market benefits from strong insurance coverage frameworks that lower barriers to patient access. Healthcare providers across primary care and specialty settings are proficient in insertion and removal procedures, reinforcing confidence in long‑term use. Ongoing public health initiatives promote awareness of the benefits of reversible contraception, encouraging adoption among a broad population. Collaboration between industry stakeholders and academic institutions fuels continuous innovation and product refinement, further strengthening market depth.
As per subdermal contraceptive implants market regional forecast, Canada reflects a supportive policy environment that prioritizes reproductive health options. Provincial health plans often include coverage for long‑acting devices, enhancing affordability for patients. The Canadian market is bolstered by a network of trained clinicians who integrate implant services into routine family planning care. Public health campaigns emphasize the convenience and efficacy of implants, contributing to steady uptake. Industry partnerships with research centres advance clinical evidence, reinforcing confidence among providers and patients alike.
European expansion is propelled by progressive health policies that prioritize gender‑inclusive family planning and equitable access to contraception. Strong public funding mechanisms reduce out‑of‑pocket costs, encouraging broader adoption across socioeconomic groups. The region’s emphasis on sustainable healthcare solutions aligns with the long‑acting nature of implants, appealing to both providers and patients. Robust clinical guidelines endorse implants as first‑line options, fostering consistent prescribing patterns. Collaborative networks among research institutions, manufacturers, and health authorities accelerate product innovation and regulatory harmonization. Growing consumer awareness through targeted educational initiatives further fuels demand, while a commitment to patient‑centered care ensures continued market momentum.
Germany is anchored by a highly organized health insurance system that provides comprehensive coverage for long‑acting devices. Clinical practice guidelines strongly endorse implants, leading to routine recommendation by obstetricians and primary care physicians. A well‑developed network of specialized clinics facilitates efficient insertion and follow‑up services. Ongoing public health programs raise awareness of reversible contraception benefits, supporting steady consumer interest. Collaboration between pharmaceutical firms and research universities drives continuous product improvement, reinforcing Germany’s dominant market position.
United Kingdom experiences accelerated growth due to national health policies that emphasize accessible reproductive health services. Integration of implants into primary care pathways enables rapid provider uptake and patient access. Public health campaigns focus on informing women of long‑acting options, thereby increasing acceptance. The NHS framework often subsidizes implant costs, minimizing financial barriers. Academic research institutions contribute robust clinical evidence that supports wider clinical endorsement. These combined influences position the United Kingdom as a fast‑growing hub for implant adoption.
France is emerging as a key segment within the broader reproductive health landscape. National health insurance schemes increasingly cover implant procedures, improving affordability for a wider audience. French medical societies endorse implants as a reliable choice, encouraging clinicians to incorporate them into standard practice. Targeted educational outreach raises patient awareness of the convenience and effectiveness of long‑acting solutions. Partnerships between biotech firms and university research centers foster innovation and clinical validation, helping to solidify the market’s emerging status.
Asia Pacific advancement stems from rapid urbanization and shifting consumer preferences toward discreet, long‑lasting contraceptive methods. Growing middle‑class populations prioritize health autonomy, driving interest in implants that require minimal follow‑up. Governments across the region are integrating family planning into national health agendas, gradually enhancing reimbursement frameworks. Increasing medical tourism and cross‑border collaborations facilitate knowledge transfer and clinical skill development. Industry investment in localized manufacturing enhances supply reliability and reduces costs, while digital health platforms expand patient education and awareness. Together these dynamics elevate the region’s role in the global implant landscape.
Japan benefits from a highly regulated healthcare system that ensures product safety and quality. National health insurance coverage for implants improves accessibility, while physician training programs promote expertise in insertion techniques. Public health initiatives emphasize the importance of long‑acting reversible contraception for women’s health empowerment. Collaborative research between pharmaceutical companies and academic institutions drives innovation tailored to local preferences. These factors collectively reinforce Japan’s steady market development.
South Korea is gaining traction through supportive government policies that prioritize reproductive health services. Insurance schemes increasingly reimburse implant procedures, lowering cost barriers for patients. Korean medical professionals receive comprehensive training, fostering confidence in offering implants as a preferred contraceptive choice. Aggressive public awareness campaigns highlight the convenience and efficacy of implants, encouraging broader acceptance. Partnerships between local manufacturers and global innovators accelerate product availability and adaptation to regional needs, strengthening South Korea’s market position.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Acceptance and Awareness
Advancements in Implant Technology
Regulatory Approval Challenges
Cost and Accessibility Concerns
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by intensified rivalry among implant manufacturers pursuing M&A to broaden product portfolios, strategic partnerships with pharmaceutical distributors to secure supply chains, and rapid tech innovation such as biodegradable polymer designs that promise longer efficacy and easier removal, driving differentiation in a market where clinical performance and cost efficiency are decisive factors.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the market is propelled primarily by growing acceptance and awareness among providers and patients, which fuels steady demand for long‑acting reversible contraception, while recent advancements in implant technology that deliver smaller, biocompatible devices and integrate digital health support act as a second driver accelerating adoption. However, regulatory approval challenges remain a notable restraint, delaying entry of new products and increasing development costs. North America continues to dominate the market due to its mature healthcare infrastructure, robust reimbursement systems and strong R&D capabilities. Within the product landscape, the Etonogestrel implants segment holds the largest share, benefiting from a trusted safety profile and simple single‑rod design. The global subdermal contraceptive implants market trend driven by increasing awareness of long-acting reversible contraception (LARC), rising demand for effective family planning methods, and expanding government and non-government initiatives to improve access to reproductive healthcare.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.2 Billion |
| Market size value in 2033 | USD 2.32 Billion |
| Growth Rate | 7.6% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Subdermal Contraceptive Implants Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Subdermal Contraceptive Implants Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Subdermal Contraceptive Implants Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Subdermal Contraceptive Implants Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Subdermal Contraceptive Implants Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.29 Billion in 2025 to USD 2.32 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).
The competitive landscape is shaped by intensified rivalry among implant manufacturers pursuing M&A to broaden product portfolios, strategic partnerships with pharmaceutical distributors to secure supply chains, and rapid tech innovation such as biodegradable polymer designs that promise longer efficacy and easier removal, driving differentiation in a market where clinical performance and cost efficiency are decisive factors. 'Organon & Co.', 'Bayer AG', 'Shanghai Dahua Pharmaceutical Co., Ltd.', 'Gedeon Richter Plc.', 'Theramex HQ UK Limited', 'Laboratorios Ariston S.A.', 'Chemo Research S.L.', 'Zydus Lifesciences Limited', 'HRA Pharma SAS', 'Mithra Pharmaceuticals SA', 'HLL Lifecare Limited', 'Pregna International Ltd.', 'Famy Care Limited', 'Janssen Pharmaceuticals, Inc.', 'Merck Sharp & Dohme (historical implant portfolio)', 'Sichuan Pharmaceutical Co., Ltd.', 'CSPC Pharmaceutical Group Limited', 'Eurogine S.L.', 'Fuqing Pharmaceutical Group', 'Helm AG'
Healthcare providers increasingly recommend subdermal contraceptive implants due to their long‑lasting efficacy and minimal maintenance, fostering patient confidence. This growing acceptance and awareness is reinforced by educational campaigns that highlight the convenience of reversible, low‑maintenance birth control, encouraging broader demographic uptake. As women seek discreet and reliable options, clinicians are more likely to discuss implants during routine visits, further embedding the method within standard family‑planning protocols and accelerating market expansion. These factors collectively enhance patient adherence and drive provider confidence, creating a virtuous cycle of adoption.
Digital Health Integration: The increasing adoption of digital health platforms is enabling remote counseling, device tracking, and adherence monitoring for subdermal contraceptive implants. Providers can schedule appointments via telehealth, while patients receive personalized reminders through mobile apps, enhancing continuation rates. Real‑time data analytics allow manufacturers to refine product designs based on usage patterns, and insurers can streamline reimbursement processes. This convergence of technology and reproductive health broadens market reach, particularly in underserved regions where conventional clinic access is limited for women worldwide today.
Why does North America Dominate the Global Subdermal Contraceptive Implants Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
